Drug Insights

Expert Tips for Searching Celecoxib on Synapse

27 February 2024
2 min read

CELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro. Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Click on the image below to begin the exploration journey of Celecoxib through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Monopar Begins Phase 1 Trial of MNPR-101-Zr Radiotherapy for Advanced Cancer
Latest Hotspot
3 min read
Monopar Begins Phase 1 Trial of MNPR-101-Zr Radiotherapy for Advanced Cancer
27 February 2024
Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.
Read →
Exploring the Latest CAR-T therapy Deal by 2seventy Bio: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest CAR-T therapy Deal by 2seventy Bio: A Guide to Rapidly Accessing Transaction Insights
27 February 2024
On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.
Read →
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
Hot Spotlight
11 min read
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
27 February 2024
Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.
Read →
FDA Approves Mabwell's IND Application for B7-H3-Targeted ADC, 7MW3711
Latest Hotspot
3 min read
FDA Approves Mabwell's IND Application for B7-H3-Targeted ADC, 7MW3711
27 February 2024
The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.